As a multi-targeted tyrosine kinase inhibitor, anlotinib potently inhibits VEGFR and blocks other kinases such as PDGFR and FGFR, suppressing HBs tumor angiogenesis through multiple pathways (23). This evidence concerns the gene PDGFRB and neoplasm.